<DOC>
	<DOCNO>NCT02557997</DOCNO>
	<brief_summary>We aim compare marker HIV reservoir , monocyte function immune activation antiretroviral therapy ( ART ) -na√Øve ( chronic infection primary infection ) , ART-controlled ART-failing HIV infect adult initiate dolutegravir ( DTG ) -based regimen . The investigator ' purpose measure cell associate HIV-1 DNA , monocyte function [ soluble CD14 ( sCD14 ) , soluble CD163 ( sCD163 ) ] , immune activation [ neopterine , interleukin-6 ( IL-6 ) high-sensitivity C-reactive protein ( hsCRP ) ] biomarkers different time point baseline week 48 post DTG-based regimen initiation group .</brief_summary>
	<brief_title>Effects Dolutegravir Based Regimen HIV-1 Reservoir Immune Activation</brief_title>
	<detailed_description />
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Male female age de 18 80 year Patient start DTGregimen Patients agree use method birthcontrol study 6 week stop DTG treatment Signed date write informed consent obtain subject subject 's legal representative prior screen Women pregnant breastfeeding HBV HCV coinfection Participation another clinical drug device trial last dose drug within past 30 day investigational medical device currently implant Documented resistance DTG Allergy intolerance study drug component drug class Any acute verify Grade 4 laboratory abnormality ( exception Grade 4 lipid ) Screening . Coadministration Dofelitide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIV reservoir</keyword>
	<keyword>HIV-1 DNA</keyword>
	<keyword>Immune activation</keyword>
	<keyword>Monocyte function</keyword>
	<keyword>Activation biomarkers</keyword>
</DOC>